An HIV protease inhibitor (EC₅₀ = 25 nM) that also inhibits CYP3A4, the primary cytochrome P450 isoform that metabolizes protease inhibitors; reduces the metabolism of concomitantly administered protease inhibitiors, enhancing their bioavailability and efficacy.